more conservative dosing for renal patients using erythropoiesis-stimulating agents

August 2011

You'll see more conservative dosing for renal patients using erythropoiesis-stimulating agents...Procrit, Epogen, Aranesp.

FDA no longer recommends targeting a specific hemoglobin concentration for these drugs in chronic kidney disease patients.

There's not an additional benefit to aiming for a hemoglobin over 11 g/dL...and it increases the risk of heart attack, stroke, and death.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote